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Introduction JPET #162396 implicated in multiple neuronal functions including reward, addiction, attention, cognition, depression, affect and movement (Albuquerque et al., 2009; Gotti et al., 2009) . There is also a smaller population of α6β2* nAChRs, which is restricted in localization to CNS catecholaminergic neurons including those in the nigrostriatal pathway, which may be involved in reward, addiction and motor activity (Drenan et al., 2008; Pons et al., 2008) . All these three nAChR subtypes (α4β2*, α6β2* and α7) have been implicated in striatal function and shown to influence striatal dopamine release (Grady et al., 2007) . In addition, studies using cyclic voltammetry indicate that this regulation of dopamine release most likely represents a complex interplay between nicotinic receptor activation and desensitization (Exley et al., 2008; Meyer et al., 2008; Perez et al., 2008) , with the latter resulting in an effective channel block similar to that observed with nAChR antagonists (Corringer et al., 2006; Picciotto et al., 2008; Buccafusco et al., 2009 ).
The objective of the present study was to gain insight into the mechanism(s) of the nicotinemediated reduction in L-dopa-induced AIMs. To achieve this, we did a series of behavioral studies to investigate the effect of different nicotine administration regimens and to determine the effect of the nicotinic receptor antagonist mecamylamine on the occurrence of L-dopainduced AIMs. We also evaluated changes in both α 4β2* and α 6β2* nAChR expression under different treatment regimens. Altogether the data suggest that nicotine may attenuate L-dopainduced dyskinesias via nAChR receptor desensitization or block. Such results are in agreement with an emerging literature that desensitization plays a critical role in nAChR-mediated function.
JPET #162396 7 recording after which rats were injected ip with 4 mg/kg amphetamine (Sigma-Aldrich Co., St.
Louis, MO). Ipsilateral full rotations (360 o
) were recorded for 90 min. Rats turning > 4 complete turns/min were used in the study.
L-dopa-induced abnormal involuntary movement (AIM) ratings
Three wks after daily injection of 8 mg/kg L-dopa methyl ester and 15 mg/kg benserazide sc (Sigma-Aldrich Co., St. Louis, MO), the rats were evaluated for AIMs, as previously described (Cenci and Lundblad, 2007; Bordia et al., 2008) . This included three different AIM components;
(1) axial AIMs, contralateral flexion of the neck and upper body that resembles dystonia-like axial torsion; (2) orolingual AIMs, which include stereotyped jaw movements, twitching of facial muscle and contralateral rapid and jerky tongue protrusion, manifested either individually or together; (3) forelimb AIMs, jerky repetitive movement of the forelimb contralateral to the lesion side, which could be fast and irregular or continuous. The above mentioned AIM components were scored on a scale from 0 to 4 based on the duration and persistence of the abnormal behavior as follows; 0 = not present; 1 = occasional; 2 = frequent; 3 = present for the entire observation time and interrupted by a loud stimulus; and 4 = present for entire observation time but not interrupted by a loud stimulus. The rats were rated at 9 time points, for 2 min each, every 20 min. The highest possible score that could be achieved in a session by each animal was 108 (highest total score per time point = 12; number of time points over 3 h = 9). All animals were habituated for a 15 min baseline before rating for L-dopa-induced AIMs.
NAChR drug treatments
One set of twenty rats was used for all the behavioral experiments described in this study.
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Three days or more washout periods were allotted between the different treatments, with L-dopa treatment continued during the washout. Control studies showed that a 3 d time interval was sufficient for L-dopa-induced AIM scores to return to control values (Bordia et al., 2008) . It is possible that L-dopa-induced AIMs may be influenced by previous dosing of agonists and antagonists; however, repeat experiments with the same doses of a specific drug yielded a similar decline in L-dopa-induced AIMs. In one series of experiments, mecamylamine (0.5 to 2 mg/kg; Sigma-Aldrich Co., St. Louis, MO) and/or nicotine (0.01 to 0.75 mg/kg; freebase, Sigma-Aldrich
Co., St. Louis, MO) were injected 30 and 10 min before L-dopa/benserazide treatment, respectively, similar to previous studies (Dekundy et al., 2007; Matta et al., 2007) . In another set of experiments, nicotine (0.1 to 2 mg/kg/day; freebase, Sigma-Aldrich Co., St. Louis, MO) or cotinine (2.5 and 5 mg/kg/day; Sigma-Aldrich Co., St. Louis, MO) was administered via osmotic minipump (Alzet model 2004, delivery rate, 0.25 μl/h; Durect Corporation, Cupertino, CA) as previously detailed (Bordia et al., 2008) .
Limb use asymmetry test
We used the forelimb asymmetry test as an index of motor function after nigrostriatal denervation. Exploratory behavior was analyzed as previously described in our laboratory (Bordia et al., 2008) and that of others (Schallert et al., 2000) . Rats were placed in a transparent cage and evaluated for contralateral forelimb use 1 h after L-dopa injection, a time at which its antiparkinsonian effects are maximal. Values are expressed as a percent of total limb use before and 1 h after L-dopa treatment. The rats were assessed for their exploratory behavior for 5 min as previously described (Bordia et al., 2008) .
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Cotinine measurements
Plasma levels of cotinine, a primary metabolite of nicotine with a relatively long half-life (Matta et al., 2007) were determined using an EIA kit (Orasure Technologies, Bethlehem, PA).
Blood samples were collected 3-4 h after nicotine injection or 2 wks after initiation of nicotine or cotinine treatment via osmotic minipump. Blood was drawn under isofluorane anesthesia from the lateral saphenous vein in heparin-coated tubes. Blood was centrifuged at 1200 g for 15 min at 
Measurement of nAChR binding sites
Another set of unilateral 6-OHDA lesioned rats were used for the binding studies. Rats were administered mecamylamine (1 mg/kg sc) or nicotine (0.2 mg/kg sc) 30 and 10 min before Ldopa/benserazide treatment, respectively, daily for 14 d. On the last day, they were killed 1 h after L-dopa treatment when its effects were maximal. The brains were quickly removed, rinsed and frozen in isopentane on dry ice. Eight μm sections were cut at -15°C in a cryostat, thaw mounted onto poly-L-lysine coated slides, dried, and stored at -80°C until use.
I-epibatidine autoradiography
125 I-epibatidine (specific activity, 2200 Ci/mmol; PerkinElmer Life and Analytical Science, Boston, MA, USA) binding was done as previously reported (Quik et al., 2003) . Thawed 8.0 μm thick striatal sections were pre-incubated at room temperature for 30 min in buffer containing 50 mM Tris, pH 7.5, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , and 1.0 mM MgCl 2 . They were incubated for 40 min with 0.015 nM 125 I-epibatidine in the presence or absence of α-conotoxinMII (300 nM) to define α4β2* nAChRs binding sites. The slides were then washed, This article has not been copyedited and formatted. The final version may differ from this version. 
I-α-conotoxinMII (α-CtxMII) autoradiography
Binding of 125 I-α-CtxMII (specific activity, 2200 Ci/mmol) was done as reported previously (Quik et al., 2003) . Eight μm striatal sections were preincubated at room temperature for 15 min in binding buffer (144 mM NaCl, 1.5 mM KCl, 2mM CaCl 2 1mM MgSO 4 , 20mM HEPES and 0.1 % BSA (bovine serum albumin), pH 7.5) plus 1 mM PMSF (phenylmethylsulfonyl fluoride)
This was followed by 1-h incubation at room temperature in binding buffer also containing 0.5% bovine serum albumin, 5 mM EDTA, 5 mM EGTA and 10 μg/ml each of aprotinin, leupeptin and pepstatin A plus 0.5 nM 125 I-α-CtxMII, . The assay was terminated by washing the slides for 10 min at room temperature, 10 min in ice cold binding buffer, twice for 10 min in 0.1X buffer at 0 O C and two final 5-s washes in ice cold deionized water. The striatal sections were air-dried and exposed to Kodak MR film (Easterman Kodak Co., Rochester, NY, USA) for 5-7 together with 3 H-microscale standards (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Nicotine (100 μM) was used to determine nonspecific binding.
[
I]RTI-121 binding
The dopamine transporter was measured using [ 125 I]RTI-121 (specific activity, 2200
Ci/mmol; PerkinElmer Life and Analytical Science, Boston, MA, USA) autoradiography as previously described (Bordia et al., 2008 Nonspecific binding was determined in the presence of the dopamine uptake inhibitor nomifensine (100 μM).
Data analyses
The optical density measurements from the autoradiograms were evaluated using ImageQuant (GE Healthcare, Little Chalfont, Buckinghamshire, UK) system and converted to fmol/mg tissue by using standard curves generated form 3 H standards. All statistical analyses were done using GraphPad Prism® (GraphPad Software, Inc, San Diego, CA.). Differences in ratings between treatment groups were determined using one-way analysis of variance (ANOVA), followed by a Dunnett's multiple comparison test. For time-course studies, repeated measures analysis of variance (ANOVA) followed by Bonferoni post hoc test was used. A level of 0.05 was considered significant. Values are the mean + S.E.M. of the indicated number of rats, and represent data pooled from one to two separate experiments.
Results
Nicotine-mediated reduction in L-dopa-induced AIMs; dose response
At the beginning of the study, lesioned rats were randomly divided into two groups such that total L-dopa-induced AIM scores were comparable in the two sets of animals (62.9 ± 6.6, 60. however, the declines appeared less pronounced than those observed with the 0.1 mg/kg dose.
Values for the saline-treated control rats remained stable over the different treatment regimes with a mean total L-dopa-induced AIM score of 69.1 ± 3.2 (n = 54, which represent the scores from 9 rats over 6 separate experiments). Total AIM values for the control group were also stable over time, with the weekly rating for the control group being 67.5 + 2.8 (n = 9 weekly experiments). It should be noted that the higher doses were also associated with the development of anxiety-like behaviors such as irritability and nervousness. Since stress (anxiety) is known to increase AIMs in Parkinson's disease patients, it is possible that these nicotine-mediated side effects enhance expression of L-dopa-induced AIMs in the rats at the higher nicotine doses.
Measurement of plasma cotinine levels (Table 1) 3 to 4 h after injection of the 0.1 mg/kg nicotine dose yielded concentrations of 202 ± 26 ng/ml (n = 10). Thus, optimal declines in Ldopa-induced AIMs are obtained with nicotine doses that result in plasma cotinine values at the lower end of those observed in the plasma of smokers (Matta et al., 2007) .
Chronic cotinine treatment does not reduce L-dopa-induced AIMs
The presence of relatively high plasma cotinine levels with nicotine treatment has led to the idea that cotinine itself may have effects in vivo. We tested this possibility by implanting cotinine containing minipumps (2.5 or 5 mg/kg/day) in 6-OHDA-lesioned rats receiving a once daily injection of L-dopa (8 mg/kg) + benserazide (15 mg/kg). These doses of cotinine were selected because they yielded plasma cotinine levels similar to those in moderate to heavy smokers (Matta et al., 2007) . The results in Table 2 show that, despite high plasma cotinine levels, 3 wks of cotinine treatment had no effect on total, axial, orolingual or forelimb AIMs.
Nicotine treatment does not worsen parkinsonism
Experiments were next done to evaluate the effect of nicotine on parkinsonism. This is important because treatments that decrease L-dopa-induced dyskinesias have also been reported to worsen motor behavior (Hsu et al., 2004) . Two behavior parameters were examined to evaluate the effect of nicotine on L-dopa-induced motor function (Bordia et al., 2008) . Fig. 2A demonstrates the effect of nicotine using the forelimb use asymmetry test, a well-characterized model that evaluates contralateral limb use after nigrostriatal damage (Schallert et al., 2000) .
These experiments were done using the dose of nicotine that optimally reduced L-dopa-induced
AIMs, that is, 0.1 mg/kg nicotine. The results show that 4 days of nicotine (0.1 mg/kg) treatment did not affect parkinsonism either ON or OFF L-dopa.
In Fig. 2B , we investigated another measure of parkinsonism, L-dopa-induced contralateral turning (Dekundy et al., 2007) . Contralateral turning was similar in rats receiving saline (677 ± 230, n=10) or nicotine (675 ± 166, n = 9), consistent with previous results (Bordia et al., 2008) . between our study and that of Gregorio et al (2009) is most likely due to the fact that we administered nicotine on a long term basis rather than acutely, with a resultant nAChR desensitization.
The reduction in L-dopa-induced AIMs requires multiple day dosing
We next determined the length of time of nicotine dosing required for an optimal reduction in L-dopa-induced AIMs. The results in Fig. 3 show that a single (acute) injection of nicotine did not attenuate L-dopa-induced AIMs. However, as previously shown, once daily nicotine injection for 4 days significantly (p < 0.01) reduced total, oral and forelimb AIMs. No further reduction in AIMs was obtained by increasing the length of nicotine treatment time (10 days).
We also tested twice daily nicotine injection for 4 days; this treatment resulted in a somewhat greater reduction in total, orolingual, and forelimb AIMs compared to once daily injection. These with a trend for reduction with once daily treatment for 10 days (Fig. 4 C , p < 0.06). The single (acute) dose regimen had no effect on L-dopa-induced AIMs (Fig. 4A ).
Chronic mecamylamine treatment reduces L-dopa-induced AIMs
This article has not been copyedited and formatted. The final version may differ from this version. We next initiated a series of experiments with the general nicotinic receptor blocker, mecamylamine as an approach to evaluate whether the effects of nicotine are receptor-mediated.
The results in Fig. 5 show that a single (acute) dose of mecamylamine (2 mg/kg) given 30 min before L-dopa had no significant effect on AIMs. However, 4 days of once daily injection of varying doses of mecamylamine significantly attenuated L-dopa-induced AIMs. Optimal efficacy was observed with the 1.0 mg/kg dose, with a significant reduction in total (P < 0.05), orolingual (P < 0.01), and forelimb (P < 0.05), and a trend for decline in axial AIMs. A 4 day treatment regimen with 0.5 and 2.0 mg/kg mecamylamine also resulted in significant reductions in orolingual (P < 0.01) and forelimb (P < 0.05) AIMs. It should be noted that mecamylamine treatment was associated with a number of transient adverse effects, including constipation and difficulty in micturation, which subsided several hours after mecamylamine injection. These effects are not unexpected since mecamylamine is a nonspecific nAChR antagonists that blocks ganglionic nicotinic receptors.
Combined effect of mecamylamine and nicotine on L-dopa-induced AIMs
We next tested the combined effect of mecamylamine and nicotine on L-dopa-induced AIMs using the multiday injection regimen described in Methods. We injected 0.1 mg/kg nicotine and/or 1.0 mg/kg mecamylamine, doses that resulted in a maximal reduction in L-dopa-induced AIMs when tested alone. Four day mecamylamine or nicotine treatment alone significantly reduced L-dopa-induced AIMs compared to saline treatment (Fig. 6) . Interestingly, the effect of combined treatment with both drugs was similar to that observed with nicotine or mecamylamine on their own (Fig. 6 ). The observation that the effect of nicotine and mecamylamine was not additive, suggests that they act via a similar mechanism. Since mecamylamine is a well-known This article has not been copyedited and formatted. The final version may differ from this version. nAChR antagonist, these data may suggest that the nicotine-mediated decline in L-dopa-induced AIMs occurs via a desensitization block.
Nicotine administration via minipump yields a similar reduction in L-dopa-induced AIMs as intermittent treatment via injection
In the experiments described thus far, nicotine was given as a bolus once or twice daily for different days via injection 10 min before the assessment of L-dopa-induced AIMs. Our previous work had shown that nicotine also reduced L-dopa-induced AIMs when given via minipump (Bordia et al., 2008) . As an approach to compare the effectiveness of these two modes of nicotine administration in reducing L-dopa-induced AIMs, we investigate the dose-response relationship for nicotine administered via minipump. Lesioned rats were surgically implanted with minipumps releasing 0.10 to 2.0 mg/kg/day nicotine or vehicle. Two wks after minipump placement, the rats were rated for L-dopa-induced AIMs as described in Methods. Low dose nicotine (0.10 and 0.25 mg/kg/day) did not significantly alter L-dopa-induced AIMs compared to vehicle-treated rats (Fig. 7) . By contrast, significant declines in total, orolingual, and forelimb AIMs were observed with the higher nicotine doses (0.5, 1.0 and 2.0 mg/kg/d), with a trend for a decrease in axial AIMs. The values for the controls remained stable with a mean total L-dopainduced AIMs score of 62.6 ± 3.8 (n = 27; which represent the scores from 9 rats over 3 separate experiments). The pattern of the dose response curve was very similar to that observed when nicotine was given via injection (see Fig. 1 ).
Plasma cotinine levels at the dose of nicotine (0.5 mg/kg/day) that resulted in a maximal reduction in L-dopa-induced AIMs were 115 ± 25 ng/ml (n = 10) (Table 1) cotinine levels at the lower end of those observed in the plasma of smokers.
Dopamine transporter
To evaluate the extent of nigrostriatal damage, we measured the dopamine transporter, a marker of the dopaminergic nerve terminal. The results in Table 3 show that there was a 99%
decline in the transporter, as anticipated, attesting to the effectiveness of the lesioning paradigm (Cenci and Lundblad, 2007; Bordia et al., 2008) .
Nicotine or mecamylamine treatment resulted in similar changes in nAChR expression in rat striatum
Rats were treated with nicotine (0.2 mg/kg) or mecamylamine (1 mg/kg) as described in the Methods, together with L-dopa/benserazide (Fig. 8) . Both nicotine and mecamylamine treatment led to a significant decrease (p < 0.01) in striatal 125 I-α-CtxMII or α 6β2 * nAChR binding sites on the unlesioned, but not lesioned side when compared to vehicle-treated rats. These data suggest that the rat striatal α 6β2* nAChR population downregulated by nicotine is lost with nigrostriatal damage.
We also performed 125 I-epibatidine binding in the presence of nonradioactive α-CtxMII to study the effects of multiple day nicotine or mecamylamine treatment on α4β2* nAChRs (Fig 8) .
Both drugs significantly increased (p < 0.01) α 4β2* binding on the unlesioned but not lesioned side compared to vehicle-treated controls. Thus, the α 4β2* nAChR population upregulated by nicotine appears to be preferentially reduced in striatum of lesioned rats, similar to the results with α 6β2* nAChR described above.
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Discussion
The present work is the first to investigate the potential mechanism(s) of the nicotine-mediated decline in L-dopa-induced dyskinesias. The results suggest that nicotine exerts its effects through an interaction at nAChRs, that nAChR desensitization may play an important role in the observed reduction in L-dopa-induced dyskinesias, and that the long-lasting nicotine metabolite cotinine is not involved in these effects. Evidence for these possibilities are discussed below.
The idea that nicotine reduces L-dopa-induced dyskinesias by interacting at nAChRs is based on our experiments with mecamylamine, an antagonist that blocks multiple nAChR subtypes.
These data show that the combined effects of mecamylamine and nicotine do not result in an additive decrease in L-dopa-induced AIMs in parkinsonian rats. One interpretation of these observations is that nicotine and mecamylamine attenuate AIMs via a shared mechanism of action, that is, by interacting at nAChRs. This idea is further supported by our studies which show that nAChR subtype agonists decrease L-dopa-induced dyskinesias in rats (Campos et al., 2009; Parameswaran et al., 2009 ).
Our studies with mecamylamine also showed that an antagonist alone reduced L-dopainduced dyskinesias to a similar extent as the agonist nicotine. The molecular basis for these seemingly discrepant observations may relate to findings that nicotine initially activates and then subsequently desensitizes or inactivates nAChRs, with a consequent receptor block (Corringer et al., 2006; Picciotto et al., 2008; Buccafusco et al., 2009 ). These observations suggest that nicotine and the antagonist mecamylamine decrease L-dopa-induced dyskinesias via nAChR blockade.
This article has not been copyedited and formatted. The final version may differ from this version. This possibility is also suggested from the results of the receptor studies. These showed that nicotine or mecamylamine both resulted in declines in α6β2* nAChRs in the unlesioned but not lesioned striatum. The agonist and antagonist also both increased α4β2* nAChRs in the unlesioned, but not lesioned striatum. The similarity in the changes in α 6β2* and α 4β2* nAChRs with nicotine and mecamylamine treatment with and without nigrostriatal damage suggests a similarity in mechanism of action, that is, that nicotine induces its effects via a receptor desensitization blockade. The α6β2* nAChRs localized to catecholaminergic neurons may also be of relevance for the observed effects of nicotine on L-dopa-induced AIMs (Grady et al., 2007; Quik et al., 2008) . The current data show that there is a very marked decline in α6β2* nAChRs with nigrostriatal damage. However, it is possible that a small remaining subset on striatal dopaminergic, and/or possibly serotonergic, neurons may play a crucial role. It is also possible that other subtypes, such as α7 nAChRs, play a role because these receptors are involved in numerous functions throughout the CNS that may be indirectly linked to the development of L-dopa-induced dyskinesias.
The decline in L-dopa-induced AIMs may be due to a direct effect of nicotine at nAChRs;
however, it could also be due to a nicotine degradation product. One such compound is cotinine, a primary nicotine metabolite with an extensive half-life (17-18 hours) (Matta et al., 2007) . The rather high circulating plasma cotinine levels after nicotine ingestion, coupled with findings that that cotinine stimulates nAChRs, has prompted the suggestion that cotinine per se may have biological effects (Dwoskin et al., 1999; O'Leary et al., 2008) . Indeed, studies show that cotinine exhibits several nicotine-like properties including effects on acoustic startle, attention and neuroprotection (Buccafusco and Terry, 2003; Buccafusco et al., 2009) . The lack of effect of administered cotinine in the current study may be due to insufficient cotinine entry into the brain such that the CNS levels were too low for efficacy (Lockman et al., 2005) . It may also relate to mode of administration. For instance, it is possible that pulsatile cotinine may have a different effect than continuous cotinine. Alternatively, the decline in L-dopa-induced AIMs may be due to a direct effect of nicotine, and/or possibly other metabolites, at the receptor.
The neural substrates that influence the nicotine-mediated reduction in L-dopa-induced dyskinesias most likely involve the nigrostriatal pathway. However, other brain regions are probably also involved since L-dopa-induced AIMs occur via integrative changes in multiple neurotransmitter systems throughout the CNS, including those present in the striatum, globus pallidus, thalamus, cortical areas, subthalamic nucleus, and cerebellum (Carta et al., 2008; Fox et al., 2008) . that is, to combat addiction. This includes the nicotine patch, gum, lozenge, nasal spray and nasal inhalant (Matta et al., 2007) . Our data would suggest that any one of these applications has potential in the treatment of L-dopa-induced dyskinesias. The final test of efficacy will require a clinical trial in subjects with Parkinson's disease patients.
This article has not been copyedited and formatted. The final version may differ from this version. However, a significant reduction in total, oral and forelimb AIMs was observed with multiple daily dosing. Each value represents mean ± S.E.M. of 9-10 rats. Significance of difference from saline control: *p < 0.05; **p < 0.01 using one-way ANOVA followed by Dunnett's multiple comparison test. ANOVA, with a trend for a decline in (C) (p < 0.063) and no effect with the acute dose in (A) (p < 0.89). Each symbol is the mean ± S.E.M. of 9-10 rats. indicates significance of difference from saline control using one-way ANOVA followed by a Dunnett's multiple comparison test. Fig. 6 . Effect of combined nicotine and mecamylamine treatment on L-dopa-induced AIMs.
Stably dyskinetic 6-OHDA-lesioned rats were injected with saline, mecamylamine (1 mg/ kg), nicotine (0.1 mg/kg) or mecamylamine (1 mg/kg) + nicotine (0.1 mg/kg), followed 30 min later by L-dopa. Treatment was for 4 consecutive days, after which axial, oral and forelimbs AIMs were assessed. Each value represents the mean ± S.E.M. of 6-8 rats. Significance of difference from saline control using two-way ANOVA followed by a Bonferoni post hoc test, *p < 0.05; **p < 0.01. Administration of the higher nicotine doses led to significant declines in total, orolingual, and forelimb AIMs, with a trend for a decrease in axial AIMs. The data represent the mean ± S.E.M.
of 9-10 rats. Significance of difference from vehicle: *p < 0.05; **p < 0.01 using one-way ANOVA followed by Dunnett's multiple comparison test. TABLE 1 Plasma cotinine levels in rats treated with nicotine or cotinine 6-OHDA-lesioned L-dopa-treated rats were administered nicotine or cotinine as indicated in the Table. Blood was drawn 3-4 h after a 4-day nicotine injection regimen, or 2 wks after nicotine or cotinine minipump implantation. Plasma cotinine levels were assessed as described in Methods.
Both 
